Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

5.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.1K
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

797
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
797
Predicting Products: SN1 vs. SN202:27

Predicting Products: SN1 vs. SN2

17.4K
Nucleophilic substitution reactions of alkyl halides can proceed via an SN1 or an SN2 mechanism. While in SN2 reactions, the nucleophile attacks the substrate simultaneously as the leaving group departs, in SN1 reactions, the substrate first dissociates to give the carbocation intermediate. Various factors such as the structure of the substrate, the strength of the nucleophile, and the nature of the solvent promote one mechanism over the other.
With increased substitution on the alkyl halide,...
17.4K
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

1.7K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.7K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

5.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.5K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

559
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
559

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute elevation of liver function test values following concomitant administration of dabigatran and primidone.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2022
Same author

Impact of a Pharmacist-Driven Poststroke Transitions of Care Clinic on 30 and 90-Day Hospital Readmission Rates.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2020
Same author

Use of virtual patient software to assess student confidence and ability in communication skills and virtual patient impression: A mixed-methods approach.

Currents in pharmacy teaching & learning·2019
Same author

New Injectable Agents for the Treatment of Type 2 Diabetes Part 2-Glucagon-Like Peptide-1 (GLP-1) Agonists.

The American journal of medicine·2018
Same author

Type 2 Diabetes Mellitus: Outpatient Insulin Management.

American family physician·2018
Same author

Effect of diseases on response to vitamin K antagonists.

Current medical research and opinion·2015

Related Experiment Video

Updated: Feb 13, 2026

Insulin Injection and Hemolymph Extraction to Measure Insulin Sensitivity in Adult Drosophila melanogaster
05:52

Insulin Injection and Hemolymph Extraction to Measure Insulin Sensitivity in Adult Drosophila melanogaster

Published on: June 30, 2011

20.4K

New Injectable Agents for the Treatment of Type 2 Diabetes Part 1 - Injectable Insulins.

Christa M George1, AhYoung Byun2, Amanda Howard-Thompson1

  • 1Department of Clinical Pharmacy, University of Tennessee Health Science Center, Memphis; Department of Family Medicine, University of Tennessee Health Science Center, Memphis.

The American Journal of Medicine
|March 3, 2018
PubMed
Summary

New insulin products offer benefits like reduced nocturnal hypoglycemia but come with higher costs. This review details the pros and cons of these advanced diabetes treatments.

Keywords:
Concentrated insulinInsulinInsulin analogType 2 diabetes

More Related Videos

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes
05:18

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

5.9K
Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets
10:09

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

10.1K

Related Experiment Videos

Last Updated: Feb 13, 2026

Insulin Injection and Hemolymph Extraction to Measure Insulin Sensitivity in Adult Drosophila melanogaster
05:52

Insulin Injection and Hemolymph Extraction to Measure Insulin Sensitivity in Adult Drosophila melanogaster

Published on: June 30, 2011

20.4K
A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes
05:18

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

5.9K
Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets
10:09

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

10.1K

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Diseases

Background:

  • The United States Food and Drug Administration (FDA) has approved novel insulin formulations.
  • These advancements aim to improve glycemic control and patient convenience.

Purpose of the Study:

  • To review the potential benefits and drawbacks of newly approved insulin products.
  • To inform healthcare providers and patients about these modern diabetes management options.

Main Methods:

  • Literature review of recent clinical studies and FDA approvals.
  • Comparative analysis of new insulin products versus traditional formulations.

Main Results:

  • New insulins may offer advantages such as decreased risk of nocturnal hypoglycemia.
  • Ease of dosing and improved pharmacokinetic profiles are potential benefits.
  • A significant disadvantage is the increased cost associated with these advanced products.

Conclusions:

  • Newly approved insulin products present a trade-off between enhanced therapeutic benefits and higher financial burden.
  • Careful consideration of efficacy, safety, and cost is essential for optimal patient care in diabetes management.